Gain-of-function Lyn induces anemia: Appropriate Lyn activity is essential for normal erythropoiesis and Epo receptor signaling

Blood

Volumn 122, Issue 2, 2013, Pages 262-271

  Slavova Azmanova, Neli S ^a   Kucera, Nicole ^a   Satiaputra, Jiulia ^a   Stone, Leah ^a,b   Magno, Aaron ^a   Maxwell, Mhairi J ^c   Quilici, Cathy ^c   Erber, Wendy ^a   Peter Klinken, S ^a   Hibbs, Margaret L ^c   Ingley, Evan ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CD71 ANTIGEN; ERYTHROID KRUPPEL LIKE FACTOR; ERYTHROPOIETIN RECEPTOR; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; GRB2 ASSOCIATED BINDING PROTEIN 2; JANUS KINASE 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN KINASE LYN; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 1; UNCLASSIFIED DRUG; ERYTHROPOIETIN; GAB2 PROTEIN, MOUSE; LYN PROTEIN-TYROSINE KINASE; PHOSPHOPROTEIN; PROTEIN TYROSINE KINASE;

ACANTHOCYTOSIS; ADULT; AGED; ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BURST FORMING UNIT E; CELL DIFFERENTIATION; COLONY FORMING UNIT E; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; ERYTHROBLAST; ERYTHROCYTE; ERYTHROID CELL; ERYTHROID PRECURSOR CELL; EXTRAMEDULLARY HEMATOPOIESIS; GAIN OF FUNCTION MUTATION; GENE DOSAGE; HEMATOCRIT; HEMOLYTIC ANEMIA; HETEROZYGOSITY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; YOUNG ADULT; ANIMAL; BLOOD; BONE MARROW; CELL LINE; CYTOLOGY; DRUG EFFECT; ENZYME ACTIVATION; ERYTHROPOIESIS; GENETICS; MEAN CORPUSCULAR VOLUME; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SPLEEN; TRANSGENIC MOUSE;

ANEMIA, HEMOLYTIC; ANIMALS; BONE MARROW; CELL DIFFERENTIATION; CELL LINE; ENZYME ACTIVATION; ERYTHROCYTE INDICES; ERYTHROCYTES; ERYTHROID PRECURSOR CELLS; ERYTHROPOIESIS; ERYTHROPOIETIN; JANUS KINASE 2; MICE; MICE, TRANSGENIC; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ERYTHROPOIETIN; SIGNAL TRANSDUCTION; SPLEEN; SRC-FAMILY KINASES;

EID: 84884481137     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-10-463158     Document Type: Article

References (49)

1. Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, Ihle JN. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell. 1993;74(2):227-236. (Pubitemid 23221699)
2. Wakao H, Harada N, Kitamura T, Mui AL, Miyajima A. Interleukin 2 and erythropoietin activate STAT5/MGF via distinct pathways. EMBO J. 1995;14(11):2527-2535.
3. Lecoq-Lafon C, Verdier F, Fichelson S, Chrétien S, Gisselbrecht S, Lacombe C, Mayeux P. Erythropoietin induces the tyrosine phosphorylation of GAB1 and its association with SHC, SHP2, SHIP, and phosphatidylinositol 3-kinase. Blood. 1999;93(8):2578-2585. (Pubitemid 29181190)
4. Bao HF, Jacobs-Helber SM, Lawson AE, Penta K, Wickrema A, Sawyer ST. Protein kinase B (c-Akt), phosphatidylinositol 3-kinase, and STAT5 are activated by erythropoietin (EPO) in HCD57 erythroid cells but are constitutively active in an EPO-independent, apoptosis-resistant subclone (HCD57-SREI cells). Blood. 1999;93(11):3757-3773. (Pubitemid 29249822)
5. Kubota Y, Tanaka T, Kitanaka A, et al. Src transduces erythropoietin-induced differentiation signals through phosphatidylinositol 3-kinase. EMBO J. 2001;20(20):5666-5677. (Pubitemid 33010044)
6. Tilbrook PA, Ingley E, Williams JH, Hibbs ML, Klinken SP. Lyn tyrosine kinase is essential for erythropoietin-induced differentiation of J2E erythroid cells. EMBO J. 1997;16(7):1610-1619. (Pubitemid 27151956)
7. Chin H, Arai A, Wakao H, Kamiyama R, Miyasaka N, Miura O. Lyn physically associates with the erythropoietin receptor and may play a role in activation of the Stat5 pathway. Blood. 1998;91(10):3734-3745.
8. Karur VG, Lowell CA, Besmer P, Agosti V, Wojchowski DM. Lyn kinase promotes erythroblast expansion and late-stage development. Blood. 2006;108(5):1524-1532. (Pubitemid 44316117)
9. Ingley E, McCarthy DJ, Pore JR, et al. Lyn deficiency reduces GATA-1, EKLF and STAT5, and induces extramedullary stress erythropoiesis. Oncogene. 2005;24(3):336-343. (Pubitemid 40188582)
10. Harder KW, Quilici C, Naik E, et al. Perturbed myelo/erythropoiesis in Lyn-deficient mice is similar to that in mice lacking the inhibitory phosphatases SHP-1 and SHIP-1. Blood. 2004;104(13):3901-3910. (Pubitemid 39620136)
11. Tilbrook PA, Palmer GA, Bittorf T, et al. Maturation of erythroid cells and erythroleukemia development are affected by the kinase activity of Lyn. Cancer Res. 2001;61(6):2453-2458. (Pubitemid 32685823)
12. Ingley E, Schneider JR, Payne CJ, McCarthy DJ, Harder KW, Hibbs ML, Klinken SP. Csk-binding protein mediates sequential enzymatic down-regulation and degradation of Lyn in erythropoietin-stimulated cells. J Biol Chem. 2006;281(42):31920-31929. (Pubitemid 46041454)
13. Harder KW, Parsons LM, Armes J, et al. Gain- and loss-of-function Lyn mutant mice define a critical inhibitory role for Lyn in the myeloid lineage. Immunity. 2001;15(4):603-615. (Pubitemid 33016445)
14. Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell. 1995;83(1):59-67.
15. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998;93(3):385-395. (Pubitemid 28232083)
16. Neubauer H, Cumano A, Müller M, Wu H, Huffstadt U, Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell. 1998;93(3):397-409. (Pubitemid 28232084)
17. Hibbs ML, Tarlinton DM, Armes J, et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell. 1995;83(2):301-311.
18. McLeod DL, Shreeve MM, Axelrad AA. Improved plasma culture system for production of erythrocytic colonies in vitro: quantitative assay method for CFU-E. Blood. 1974;44(4):517-534.
19. Klinken SP, Holmes KL, Fredrickson TN, Erner SM, Morse HC III. Phenylhydrazine stimulates lymphopoiesis and accelerates Abelson murine leukemia virus-induced pre-B cell lymphomas. J Immunol. 1987;139(9):3091-3098. (Pubitemid 17157484)
20. Klinken SP, Nicola NA, Johnson GR. In vitro-derived leukemic erythroid cell lines induced by a raf- and myc-containing retrovirus differentiate in response to erythropoietin. Proc Natl Acad Sci USA. 1988;85(22):8506-8510. (Pubitemid 19024991)
21. Ingley E, Chappell D, Poon SY, et al. Thyroid hormone receptor-interacting protein 1 modulates cytokine and nuclear hormone signaling in erythroid cells. J Biol Chem. 2001;276(46):43428-43434.
22. Hibbs ML, Harder KW, Armes J, et al. Sustained activation of Lyn tyrosine kinase in vivo leads to autoimmunity. J Exp Med. 2002;196(12):1593-1604. (Pubitemid 36026471)
23. Bulut GB, Sulahian R, Ma Y, Chi NW, Huang LJ. Ubiquitination regulates the internalization, endolysosomal sorting, and signaling of the erythropoietin receptor. J Biol Chem. 2011;286(8):6449-6457.
24. Constantinescu SN. Mechanism of erythropoietin receptor activation. In: Molineux G, Elliott SG, eds. Erythropoietins, Erythropoietic Factors, and Erythropoiesis. Foote, MA: Birkhäuser Basel; 2009:175-196.
25. Flores-Morales A, Pircher TJ, Silvennoinen O, et al. In vitro interaction between STAT5 and JAK2; dependence upon phosphorylation status of STAT5 and JAK2. Mol Cell Endo. 1998;138(1-2):1-10. (Pubitemid 28302012)
26. Takeda Y, Nakaseko C, Tanaka H, et al. Direct activation of STAT5 by ETV6-LYN fusion protein promotes induction of myeloproliferative neoplasm with myelofibrosis. Br J Haematol. 2011;153(5):589-598.
27. Ingley E. Integrating novel signaling pathways involved in erythropoiesis. IUBMB Life. 2012;64(5):402-410.
28. Zhu QS, Robinson LJ, Roginskaya V, Corey SJ. G-CSF-induced tyrosine phosphorylation of Gab2 is Lyn kinase dependent and associated with enhanced Akt and differentiative, not proliferative, responses. Blood. 2004;103(9):3305- 3312. (Pubitemid 38525657)
29. Futami M, Zhu QS, Whichard ZL, et al. G-CSF receptor activation of the Src kinase Lyn is mediated by Gab2 recruitment of the Shp2 phosphatase. Blood. 2011;118(4):1077-1086.
30. Wickrema A, Uddin S, Sharma A, et al. Engagement of Gab1 and Gab2 in erythropoietin signaling. J Biol Chem. 1999;274(35):24469-24474.
31. Lynch DK, Daly RJ. PKB-mediated negative feedback tightly regulates mitogenic signalling via Gab2. EMBO J. 2002;21(1-2):72-82. (Pubitemid 34087076)
32. Yi T, Zhang J, Miura O, Ihle JN. Hematopoietic cell phosphatase associates with erythropoietin (Epo) receptor after Epo-induced receptor tyrosine phosphorylation: identification of potential binding sites. Blood. 1995;85(1):87-95.
33. Zhang SQ, Yang WT, Kontaridis MI, et al. Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol Cell. 2004;13(3):341-355. (Pubitemid 38229807)
34. Chen R, Kim O, Yang J, et al. Regulation of Akt/PKB activation by tyrosine phosphorylation. J Biol Chem. 2001;276(34):31858-31862.
35. Yang KJ, Shin S, Piao L, et al. Regulation of 3-phosphoinositide- dependent protein kinase-1 (PDK1) by Src involves tyrosine phosphorylation of PDK1 and Src homology 2 domain binding. J Biol Chem. 2008;283(3):1480-1491.
36. Rhodes MM, Kopsombut P, Bondurant MC, Price JO, Koury MJ. Bcl-x(L) prevents apoptosis of late-stage erythroblasts but does not mediate the antiapoptotic effect of erythropoietin. Blood. 2005;106(5):1857-1863. (Pubitemid 41208605)
37. Sasaki A, Yasukawa H, Shouda T, Kitamura T, Dikic I, Yoshimura A. CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J Biol Chem. 2000;275(38):29338-29347. (Pubitemid 32043805)
38. Brunati AM, Bordin L, Clari G, et al. Sequential phosphorylation of protein band 3 by Syk and Lyn tyrosine kinases in intact human erythrocytes: identification of primary and secondary phosphorylation sites. Blood. 2000;96(4):1550-1557. (Pubitemid 30658490)
39. De Franceschi L, Fumagalli L, Olivieri O, Corrocher R, Lowell CA, Berton G. Deficiency of Src family kinases Fgr and Hck results in activation of erythrocyte K/Cl cotransport. J Clin Invest. 1997;99(2):220-227. (Pubitemid 27060715)
40. De Franceschi L, Tomelleri C, Matte A, et al. Erythrocyte membrane changes of chorea-acanthocytosis are the result of altered Lyn kinase activity. Blood. 2011;118(20):5652-5663.
41. Sturgeon CM, Chicha L, Ditadi A, et al. Primitive erythropoiesis is regulated by miR-126 via nonhematopoietic Vcam-1+ cells. Dev Cell. 2012;23(1):45-57.
42. Bouscary D, Pene F, Claessens Y-E, et al. Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. Blood. 2003;101(9):3436-3443. (Pubitemid 36857926)
43. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96(6):857-868. (Pubitemid 29165088)
44. You H, Pellegrini M, Tsuchihara K, et al. FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J Exp Med. 2006;203(7):1657-1663. (Pubitemid 44036270)
45. Koulnis M, Porpiglia E, Porpiglia PA, Liu Y, Hallstrom K, Hidalgo D, Socolovsky M. Contrasting dynamic responses in vivo of the Bcl-xL and Bim erythropoietic survival pathways. Blood. 2012;119(5):1228-1239.
46. Hibbs ML, Harder KW. The duplicitous nature of the Lyn tyrosine kinase in growth factor signaling. Growth Factors. 2006;24(2):137-149.
47. Xu Y, Harder KW, Huntington ND, Hibbs ML, Tarlinton DM. Lyn tyrosine kinase: accentuating the positive and the negative. Immunity. 2005;22(1):9-18. (Pubitemid 40143447)
48. Ingley E. Functions of the Lyn tyrosine kinase in health and disease. Cell Commun Signal. 2012;10(1):21.
49. Socolovsky M, Nam H, Fleming MD, Haase VH, Brugnara C, Lodish HF. Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood. 2001;98(12):3261-3273.